JAMP and Alvotech Announce Canadian Approval of SIMLANDI™
20 janvier 2022
Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market High-concentration formulations, previously unavailable in Canada, reflect over 80% of use in the US Market. SIMLANDI is the first biosimilar candidate to be approved under the Alvotech/JAMP collaboration
Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian market
High-concentration formulations, previously unavailable in Canada, reflect over 80% of use in the US Market. SIMLANDI is the first biosimilar candidate to be approved under the Alvotech/JAMP collaboration